Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two ...

There are now positive results from five late-stage trials on retatrutide, which Lilly is positioning as the next pillar of ...

Two of the world's biggest pharmaceutical companies are headed to court after Novo Nordisk, the maker of Ozempic and a ...

A rival drug maker is taking aim at Eli Lilly in a major lawsuit, claiming the company purposely used old data in an ad ...

Novo Nordisk, the maker of Wegovy, has filed a lawsuit on Tuesday against competitor Eli Lilly alleging that its GLP-1 ...

Novo Nordisk A/S sued Eli Lilly & Co., accusing its rival of misleading advertising as competition in the U.S. market for ...

Eli Lilly will seek regulatory approval for retatrutide, a powerful weight loss drug that a new study shows helped people lose nearly 56 pounds on average.

Eli Lilly & Co.’s highly anticipated next-generation weight-loss shot didn’t increase overall heart risk in a new study, the ...

Novo Nordisk just sued Eli Lilly over weight-loss drug ads, but the moment the lawsuit hit, investors moved in exactly the ...

Novo Nordisk is suing Eli Lilly over its GLP-1 ads, accusing the rival drugmaker of false advertising for claiming Lilly’s ...

Novo Nordisk sues Eli Lilly over GLP-1 weight-loss drug ads comparing Zepbound vs Wegovy doses; see what’s alleged, why it ...

Novo Nordisk says Eli Lilly’s blockbuster weight-loss comparison became misleading after Wegovy’s dose increased.